ArticleJournal of immunotherapy and precision oncology2022
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.
Article in Journal of immunotherapy and precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Moving Beyond the Plateau in Immune Checkpoint Inhibition-The Imperative of Early Referral and Precision Strategies.Journal of immunotherapy and precision oncology · 2026Article
- CYLD Mutations, PD-L1 and HPV; A Pan-Cancer Landscape Analysis.Research square · 2026Article
- Growth hormone receptor antagonism improves tumoral chemo-immunotherapy response in a mouse model of lung cancer.Translational oncology · 2026Article
- Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy.NPJ precision oncology · 2026Article
- Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.Journal of immunotherapy and precision oncology · 2026Review
- High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.JCO oncology advances · 2026Article
- OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes.Therapeutic advances in medical oncology · 2026Article
- Dual inhibition of CSF-1R and IDO modulates the fibrotic and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Article
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies.Seminars in cancer biology · 2025Review
- Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma.The Indian journal of medical research · 2025Article
- Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.Dermatopathology (Basel, Switzerland) · 2025Review
- Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly.Cancer metastasis reviews · 2025Review
- PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome.NPJ genomic medicine · 2025Article
- Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype.Frontiers in immunology · 2025Review
- OX40/OX40 ligand and its role in precision immune oncology.Cancer metastasis reviews · 2024Review
- DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024Article
- The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Introduction: Many studies have focused on the role of programmed death receptor ligand 1 (PD-L1) expression in predicting immunotherapy outcomes. Limited clinical data are available regarding the role of programmed death receptor 1 (PD-1; the PD-L1 receptor) expressing tumor-infiltrating lymphocytes (TILs) in PD-1/PD-L1 antibody responsiveness. However, preclinical studies demonstrate that TILs expressing PD-1 contribute to tumor immune evasion. Methods: This study analyzed the association between TIL-PD-1 status and outcome after immune checkpoint blockade (ICB) therapy. We evaluated 123 patients with various solid tumors treated with monoclonal antibodies targeting the PD-1/PD-L1 signaling axis. Additionally, 8706 solid tumor specimens were assessed for TIL-PD-1 and tumor mutational burden (TMB) status. Results: The presence of PD-1-expressing TILs in tumors was associated with increased median progression-free survival (7.0 vs 1.9 months; Conclusion: TIL-PD-1 positivity in tumors (≥ 1%) is associated with significantly longer progression-free and overall survival after ICB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.